CorMedix Inc at HC Wainwright Investment Conference - New York Transcript
Good afternoon, everyone, and thank you for joining the 25 Annual H.C Wainwright Global Investment Conference. My name is Trevor levy, and I'm on the investment banking team at H.C. Wainwright. I would now like to introduce our next presenter. Please welcome Joe to discuss the CEO, and Matthew David, the CFO of CorMedix.
Thank you, Trevor, and thank you to the Wainwright team for having us here today to present the company. Just firstly refer to on page 2 here are forward-looking statements on this reflects some of the things we'll be talking about today.
So first, we start off with some background, who is CorMedix? CorMedix is a publicly listed small-cap pre-commercial stage biopharma company, developing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.
A lead asset that we'll talk about today is DefenCath, novel, first-in-class non-antibiotic antimicrobial catheter lock solution designed to reduce
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |